EUCTR2006-002902-74-LV进行中（未招募）不适用
A double-blind, double-dummy, randomized, controlled, multi-centre study of the activity and safety of 2 daily doses of EMD 387008 versus placebo and metformin in parallel groups after 8 weeks of treatment in type 2 diabetic subjects. - DEEP study
Merck Santé s.a.s.0 个研究点开始时间: 2006年8月28日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male and female type 2 diabetic subjects who are not receiving antidiabetic treatment or who are being treated with antidiabetic monotherapy including metformin, sulfonylurea, glinide or acarbose·
- •- Age between 18 and 70 years·
- •- Body mass index (BMI) >=20 and <40 kg/m²·
- •- Fasting plasma glucose >=7.8 mmol/L and <=13.3 mmol/L (>=140 mg/dL and <=240 mg/dL) at Visit 4a·
- •- HbA1c <=10%, at screening visit.
- •- No treatment with thiazolidinediones or insulin within 3 months before randomization·
- •- No treatment with statin or fibrate within 3 months before randomization·
- •- Creatinine clearance equal or above 60 mL/[min*1.73 m2] as estimated by the Modification of Diet in Renal Disease (MDRD) formula·
- •- Albuminuria of <300 µg/mg creatininuria·
- •- No acute cardiovascular event within 3 months before randomization·
- •- Effective contraception for women if the risk for conception exists·
- •- Subject has given written informed consent before any study-related activities are carried out
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Any disease which in the investigator’s opinion would exclude the subject from the study·
- •- Acute or chronic diseases which can cause severe tissue hypoxia, e.g. cardiac and respiratory insufficiency or acute myocardial infarction·
- •- Acute conditions which can impair renal function, e.g. dehydration or severe infections·
- •- Uncontrolled high blood pressure [BP] (diastolic BP >100 mmHg or systolic BP >180 mmHg)·
- •- History of drug-induced Torsade de Pointes, or presence of a familial long QT syndrome·
- •- Impairment of hepatic function (alkaline phosphatase or aspartate aminotransferase [AST], or alanine aminotransferase [ALT] >3 x the upper limit of normal)·
- •- Evidence of retinopathy of severity >=35, in the Classification of Retinopathy Severity (Early Treatment Diabetic Retinopathy Study (assessed by an ophthalmologist in the 6 months preceding inclusion)·
- •- Pregnancy or lactation·
- •- History of any clinically important neurological disorders and/or epilepsy·
- •- Mental handicap, legal incapacity, or any history of clinically important emotional and/or psychiatric illness·
- •- Presence of a contraindication to the study medication, including metformin·
- •- Known hypersensitivity to any of the constituents or excipients of the study drug and metformin tablets, or history of relevant drug and/or food allergies (e.g. anaphylactic, anaphylactoid reactions)·
- •- Change in currently used medication and/or use of any new prescription or non-prescription medication within 14 days prior to randomization. The occasional use of paracetamol is not prohibited·
- •- Positive screen for hepatitis B surface antigen (HbsAg), antibody to the hepatitis A virus (anti-HAV; immunoglobulin M [IgM]), antibody to hepatitis C virus (anti-HCV) or antibodies to human immunodeficiency virus (anti-HIV) 1 and 2 at screening·
- •- Any history of alcohol abuse or drug addiction·
- •- Smoking of more than 10 cigarettes or 3 cigars or 3 pipes per day ·
- •- Participation in a clinical study within 60 days before randomization ·
- •- Donation of blood within 90 days before randomization
研究者
相似试验
进行中（未招募）
1 期
A double blind, prospective, randomised, controlled clinical trial to evaluate the effect of topical phenytoin, on healing, in diabetic foot ulcers. - noneDiabetes Mellitus and associated diabetic foot ulcerationEUCTR2004-004787-74-GBRoyal Group of Hospitals Trust144
已完成
不适用
Safety and Efficacy of Loxoprofen Sodium cataplasm Ointment Against Knee OsteoarthritisMusculoskeletal DiseasesGonarthrosis [arthrosis of knee]Knee osteoarthritisISRCTN40097939ead Chemical Co. Ltd (Japan)160
已完成
不适用
Safety and Efficacy of Loxoprofen Sodium cataplasm Ointment Against Swelling and Pain caused By Trauma (SELSOASPBT)ISRCTN10182003ead Chemical Co. Ltd (Japan)160
尚未招募
不适用
A randomized, double-blind, prospective, controlled trial for Yishen-Tongbi-Tang in the treatment of active rheumatoid arthritisRheumatoid ArthritisITMCTR1900002503The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
尚未招募
不适用
A Study to compare the effect of three drugs -Dexmedetomidine, Lidocaine and Fentanyl in increasing heart rate and blood pressure in response to Laryngoscopy and Intubation in patients undergoing Cardiac SurgeryCTRI/2022/05/042885Department of Anaesthesiology